Here’s Why IDEXX Laboratories (IDXX) Shares are Re-Rating to Historical Average

Core Insights - Conestoga Capital Advisors reported a -5.75% return for its Mid Cap Strategy in Q4 2025, underperforming the Russell Midcap Growth Index which returned -3.70% [1] - The full year 2025 saw the Mid Cap Composite return -4.73%, significantly trailing the benchmark return of 8.66% [1] Company Overview: IDEXX Laboratories, Inc. - IDEXX Laboratories, Inc. is a leading US-based healthcare company focused on diagnostics and testing for veterinary, food, and water applications [3] - As of February 19, 2026, IDEXX's stock closed at $630.73 per share, with a market capitalization of $50.461 billion [2] - Over the past month, IDEXX's stock delivered a -9.10% return, but gained 39.30% over the past twelve months [2] Performance and Market Position - IDEXX has shown resilient organic revenue growth despite weak veterinary traffic trends and has consistently beaten earnings expectations [3] - The company is not among the 30 most popular stocks among hedge funds, with 55 hedge fund portfolios holding its shares at the end of Q3 2025, an increase from 48 in the previous quarter [4] - While IDEXX is recognized for its potential, the company faces competition from certain AI stocks that are perceived to offer greater upside potential and lower downside risk [4]